There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Zynerba Pharmaceuticals (NASDAQ:ZYNE), Alnylam Pharma (NASDAQ:ALNY) and Intercept Pharma (NASDAQ:ICPT) with bullish sentiments.
Zynerba Pharmaceuticals (ZYNE)
In a report released today, Arlinda Lee from Canaccord Genuity maintained a Buy rating on Zynerba Pharmaceuticals, with a price target of $15. The company’s shares opened today at $5.73, close to its 52-week low of $5.42.
According to TipRanks.com, Lee is a 1-star analyst with an average return of -0.1% and a 41.3% success rate. Lee covers the Healthcare sector, focusing on stocks such as Eloxx Pharmaceuticals Inc, Karyopharm Therapeutics, and Aquinox Pharmaceuticals.
Zynerba Pharmaceuticals has an analyst consensus of Strong Buy, with a price target consensus of $20.33, representing a 254.8% upside. In a report released today, Cantor Fitzgerald also reiterated a Buy rating on the stock with a $20 price target.
.
See today’s analyst top recommended stocks >>
Alnylam Pharma (ALNY)
Needham analyst Alan Carr maintained a Buy rating on Alnylam Pharma today and set a price target of $152. The company’s shares opened today at $95.22.
Carr noted:
“Alnylam mgmt hosted a conference call today to provide a quarterly corporate update. EMA CHMP recently issued a positive opinion for Onpattro and we expect approval in Europe in Sept 2018. We also expect FDA approval next week by the 8/11/18 PDUFA date. We assume FDA label will be similar to that of EMA. Alnylam announced this morning a streamlined path to market for TTRsc02, w/ plans to initiate an open-label historical comparator trial in hATTR-PN patients 2H18. Interim analysis of Phase 3 givosiran trial remains on track for Sept 2018 and lumasiran Phase 3 trial start is unch for 3Q18. Mgmt guiding for RNAi platform to put at least one new drug on the market each year through 2021. BUY.”
According to TipRanks.com, Carr is a 3-star analyst with an average return of 3.4% and a 40.6% success rate. Carr covers the Healthcare sector, focusing on stocks such as Biohaven Pharmaceutical Holding Co Ltd, Rhythm Pharmaceuticals Inc, and Lexicon Pharmaceuticals.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Alnylam Pharma with a $153.50 average price target, implying a 61.2% upside from current levels. In a report issued on July 23, Piper Jaffray also reiterated a Buy rating on the stock with a $160 price target.
.
Intercept Pharma (ICPT)
Cowen & Co. analyst Ritu Baral maintained a Buy rating on Intercept Pharma today and set a price target of $120. The company’s shares opened today at $100.83.
According to TipRanks.com, Baral is a top 100 analyst with an average return of 35.6% and a 54.6% success rate. Baral covers the Healthcare sector, focusing on stocks such as Madrigal Pharmaceuticals Inc, Allena Pharmaceuticals Inc, and Global Blood Therapeutics.
Currently, the analyst consensus on Intercept Pharma is a Moderate Buy with an average price target of $116.33.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
